|
[posting]62151863[/posting]Die bisherigen Daten von ADO-09 sind sehr vielversprechend wenn die sich in der neuen Studie weiter bestätigen dann wie gesagt gibts bestimmt einen saftigen Kurssprung . Verstehe nicht warum solche attraktive Biotechs in Frankreich so übest unterbewertet sind . ADO09, a co-formulation of the amylin-analog pramlintide and the A21G human insulin analog, lowers postprandial blood glucose versus insulin lispro in type 1 diabetes https://www.adocia.com/wp-content/uploads/2019/09/PR_ADOCIA_… “We are excited to share, through these promising initial clinical results, the potential of ADO09, our breakthrough coformulation of prandial insulin and pramlintide for the treatment of type 1 diabetes (T1D).” said Olivier Soula, Deputy General Manager and Director of R&D at Adocia.“With this coformulation, we aim to finally deliver on the promise of pramlintide for people with T1D, this therapeutic agent havingdemonstrated remarkable medical benefits, including better postprandial glycemic control and a constellation of other benefits that no other commercial treatment offers them today.” Adocia develops faster, more physiologic insulins to improve the lives of people with diabetes. Eve-Marie, T1D, shares her daily life struggles and her hopes for improved life with diabetes. https://www.adocia.com/france-3-auvergne-rhone-alpes-french-… |
|
| aus der Diskussion: | ADOC.PA (Mkap €58 M) Cash €45 M --HOT Diabetes Pipeline |
| Autor (Datum des Eintrages): | Biohero (13.12.19 16:02:37) |
| Beitrag: | 3 von 74 (ID:62153639) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |